Aptitude Medical Systems

Aptitude Medical Systems is a private, commercial-stage diagnostics company developing the Metrix platform, a next-generation, handheld molecular diagnostic system. Its lead product is the FDA-authorized Metrix COVID-19 Test for at-home and over-the-counter use, representing a significant regulatory milestone as the first such authorized molecular test using saliva or swab without a prescription. The company is leveraging this platform to build a pipeline targeting respiratory, sexual health, and other conditions, aiming to capture value in the decentralized testing market by improving access and economics for healthcare providers and consumers.

Metrix: A handheld, easy-to-use platform enabling lab-quality PCR testing in minutes at point-of-need (e.g., clinics, home). Designed for use with saliva or swab samples and operates without physician supervision.

Aptitude competes in the point-of-care molecular diagnostics space against companies like Cue Health (molecular OTC tests), Lucira (acquired by Pfizer), and BioFire (larger syndromic panels for clinical settings). It also faces broad competition from rapid antigen test providers (Abbott, Quidel) and traditional central lab services. Its key differentiator is combining true PCR quality with a simple, handheld format authorized for OTC use.